2. GPCR/G Protein
  3. Endothelin Receptor
  4. Avosentan

Avosentan  (Synonyms: Ro 67-0565; SPP-301)

Cat. No.: HY-15195 Purity: 98.15%
COA
SDS
Handling Instructions Technical Support

Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.

For research use only. We do not sell to patients.

Avosentan

Avosentan Chemical Structure

CAS No. : 290815-26-8

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Avosentan:

Avosentan Related Antibodies

Top Publications Citing Use of Products

View All Endothelin Receptor Isoform Specific Products:

View All Isoforms
ETA ETB

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure[1][2][3][4].

IC50 & Target[1][2][3][4]

ETA

 

In Vitro

Avosentan (0.01-1 μM, 30 min) has no direct effect on quiescent vessels but has a strong inhibitory effect on the endothelin-1 induced contractions in isolated porcine ciliary arteries and shows stronger effect in endothelium-denuded vessels[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Avosentan Related Antibodies
In Vivo

Avosentan (Incremental doses of 0.003-3 mg/kg, i.v., at 30-min intervals) inhibits ETB receptor-mediated effects and consequently leads to acute fluid retention in anesthetized rats[1].
Avosentan (0.1-100 mg/kg, i.g., single dose or once daily for 5 weeks) is protective in hypertensive nephropathy at doses not causing fluid retention in rats[3].
Avosentan (0.003%-0.3%, topically applied to the glaucomatous eye, twice daily for 5 days) reduces intraocular pressure (IOP) in glaucomatous monkey eyes in a dose-dependent manner[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Renal excretory function assay established male Sprague-Dawley (SD) rats (12-14 weeks)[1]
Dosage: Incremental doses of 0.003, 0.03, 3 mg/kg, BQ-788 (HY-15894A) was administered 30 min after the highest dose
Administration: Intravenous administration (i.v.), at 30-min intervals
Result: Decreased urine output and fractional excretion of water in a concentration-dependent manner.
Returned sodium excretion to control values and slightly decreased mean arterial pressure (MAP)
Did not further decrease urine output or water excretion and was without effect.
Significantly decreased hematocrite.
Animal Model: Hypertensive nephropathy model established male double transgenic rats (dTGR) with human angiotensinogen and renin genes[3]
Dosage: 0.1, 1, 10, 100 mg/kg (single dose) and 10 mg/kg (long-term)
Administration: Oral gavage (i.g.), single dose or once daily for 5 weeks
Result: Caused 18.3% decrease in diuresis, 8.3% drop in hematocrit at 100 mg/kg and No significant fluid retention at 10 mg/kg.
Reduced proteinuria and significantly lowered the scores of renal glomerular fibrosis and other damages after 5-week treatments.
Significantly increased survival rate combined with Valsartan (HY-18204).
Animal Model: IOP model established in adult female cynomolgus monkeys each weighing 3-5 kg, in which glaucoma had been induced unilaterally by repeated diode laser photocoagulation of the mid-trabecular meshwork[4]
Dosage: Topically applied to the glaucomatous eye, twice daily for 5 days
Administration: Oral gavage (i.g.), single dose or once daily for 5 weeks
Result: Significantly reduced IOP only at 2 hrs after the first dose, and at 2 and 3 hrs after the 9th dose.
Produced a longer duration of action at 0.03% and 0.3% concentrations.
No anterior chamber cellular response was observed in any eye during the 5 days of treatment by slit-lamp examination.
Clinical Trial
Molecular Weight

479.51

Formula

C23H21N5O5S
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

COC1=C(OC(C(NS(C2=NC=C(C=C2)C)(=O)=O)=NC(C3=CC=NC=C3)=N4)=C4OC)C=CC=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 6.67 mg/mL (13.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0855 mL 10.4273 mL 20.8546 mL
5 mM 0.4171 mL 2.0855 mL 4.1709 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 0.67 mg/mL (1.40 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 0.67 mg/mL (1.40 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.0855 mL 10.4273 mL 20.8546 mL 52.1366 mL
5 mM 0.4171 mL 2.0855 mL 4.1709 mL 10.4273 mL
10 mM 0.2085 mL 1.0427 mL 2.0855 mL 5.2137 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Avosentan Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Avosentan290815-26-8Ro 67-0565 SPP-301SPP301SPP 301SPP-301Endothelin ReceptorHypertensive nephropathyEndothelin receptor antagonistAngiotensin receptor antagonistFluid retention Glaucoma monkeyIntraocular pressureIsolated ciliary arteriesMyographyInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Avosentan
Cat. No.:
HY-15195
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.